<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
ESAIY
Eisai
$
()


  • Biogen reports Leqembi approved for treatment of Alzheimer's in Israel

    7/12/2024 - 06:09am
  • Biogen announces Hong Kong has approved Leqembi to treat Alzheimer's

    7/10/2024 - 20:30pm
  • Eisai to begin enrolling study in patients with narcolepsy

    7/8/2024 - 09:46am
  • Eisai just downgraded at BofA, here's why

    7/3/2024 - 10:53am
  • Biogen's Lecanemab launched in China to treat Alzheimer's Disease

    6/27/2024 - 19:50pm
  • RBC believes Leqembi on track for EU approval after speaking to Biogen

    6/26/2024 - 15:19pm
  • Biogen reports Leqembi approved for treatment of Alzheimer's in South Korea

    5/28/2024 - 07:19am
  • Biogen says won't exercise option to license and lead development of BIIB121

    5/16/2024 - 12:37pm
  • Eisai says CHMP oral explanation for lecanemab rescheduled

    3/22/2024 - 09:23am
  • Ligand partner Eisai receives Japan approval for Fycompa injection

    2/22/2024 - 16:13pm
  • What You Missed On Wall Street This Morning

    2/5/2024 - 11:56am
  • Eisai expects 1,500 Alzheimer's patients in China launch, Reuters says

    2/4/2024 - 19:01pm
  • PDS Biotechnology CMO Lauren Wood retires, Kirk Shepard succeeds

    1/22/2024 - 16:48pm
  • Eisai says SAG to discuss MAA for lecanemab by European Medicines Agency

    1/11/2024 - 07:07am
  • Biogen, Eisai report Leqembi approved in China for Alzheimer's treatment

    1/9/2024 - 06:04am
dynamic_feed Breaking News